- 2017, CRODA International PLC acquired part of the patent portfolio covering the use of adjuvants for Vaccine applications.
- CRODA International PLC has manufacturing rights to the product in question.
- These types of particles (ISCOM) have been commercialized in Novavax Inc.´s Covid vaccine, NVX-CoV2373.
Our In-vitro studies have identified three saponin-based formulations and have demonstrated efficacy against solid and non-solid cancer tumors
The Canqura patent portfolio consists of the “Killcan” family which derives from the PCT application WO 2008/063129 filed in 2007, and the “G3” EP application which derives from WO 2013/051994 filed in 2012. Both application families relate to the use of certain (nano)particles in cancer therapy. The inventions described in the two application families mainly differ in the way the (nano)particles have been defined (i.e. what they contain and their morphology).